ERBB3 and ovarian cancer: Interestingly, the level of HER2 in ovarian cancer below which seribantumab provides benefit (~126,000 receptors/cell) closely matches the level predicted by computational modeling and preclinical experiments in which seribantumab potently inhibits ErbB3 phosphorylation (Figures 6c and d).